187 related articles for article (PubMed ID: 38191620)
1. Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profiling.
Raybould MIJ; Turnbull OM; Suter A; Guloglu B; Deane CM
Commun Biol; 2024 Jan; 7(1):62. PubMed ID: 38191620
[TBL] [Abstract][Full Text] [Related]
2. The Therapeutic Antibody Profiler for Computational Developability Assessment.
Raybould MIJ; Deane CM
Methods Mol Biol; 2022; 2313():115-125. PubMed ID: 34478133
[TBL] [Abstract][Full Text] [Related]
3. Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries.
Azevedo Reis Teixeira A; Erasmus MF; D'Angelo S; Naranjo L; Ferrara F; Leal-Lopes C; Durrant O; Galmiche C; Morelli A; Scott-Tucker A; Bradbury ARM
MAbs; 2021; 13(1):1980942. PubMed ID: 34850665
[TBL] [Abstract][Full Text] [Related]
4. Five computational developability guidelines for therapeutic antibody profiling.
Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520
[TBL] [Abstract][Full Text] [Related]
5. Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment.
Negron C; Fang J; McPherson MJ; Stine WB; McCluskey AJ
MAbs; 2022; 14(1):2080628. PubMed ID: 35771588
[TBL] [Abstract][Full Text] [Related]
6. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.
Khetan R; Curtis R; Deane CM; Hadsund JT; Kar U; Krawczyk K; Kuroda D; Robinson SA; Sormanni P; Tsumoto K; Warwicker J; Martin ACR
MAbs; 2022; 14(1):2020082. PubMed ID: 35104168
[TBL] [Abstract][Full Text] [Related]
7. Antigen nature and complexity influence human antibody light chain usage and specificity.
Smith K; Shah H; Muther JJ; Duke AL; Haley K; James JA
Vaccine; 2016 May; 34(25):2813-20. PubMed ID: 27113164
[TBL] [Abstract][Full Text] [Related]
8. Production and immunodiagnostic applications of antihuman light chain monoclonal antibodies.
Abe M; Goto T; Kennel SJ; Wolfenbarger D; Macy SD; Weiss DT; Solomon A
Am J Clin Pathol; 1993 Jul; 100(1):67-74. PubMed ID: 7688492
[TBL] [Abstract][Full Text] [Related]
9. Human placenta: relative content of antibodies of different classes and subclasses (IgG1-IgG4) containing lambda- and kappa-light chains and chimeric lambda-kappa-immunoglobulins.
Lekchnov EA; Sedykh SE; Dmitrenok PS; Buneva VN; Nevinsky GA
Int Immunol; 2015 Jun; 27(6):297-306. PubMed ID: 25644595
[TBL] [Abstract][Full Text] [Related]
10. Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics.
Zhang W; Wang H; Feng N; Li Y; Gu J; Wang Z
Antib Ther; 2023 Jan; 6(1):13-29. PubMed ID: 36683767
[TBL] [Abstract][Full Text] [Related]
11. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.
Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L
MAbs; 2020; 12(1):1743053. PubMed ID: 32249670
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
[TBL] [Abstract][Full Text] [Related]
13. Structure-Based Optimization of Antibody-Based Biotherapeutics for Improved Developability: A Practical Guide for Molecular Modelers.
Thorsteinson N; Comeau SR; Kumar S
Methods Mol Biol; 2023; 2552():219-235. PubMed ID: 36346594
[TBL] [Abstract][Full Text] [Related]
14. Antibody response elicited by T-dependent and T-independent antigens in gene targeted kappa-deficient mice.
Pricop L; Brumeanu T; Elahi E; Moran T; Wang BS; Troustine M; Huszar D; Alt F; Bona C
Int Immunol; 1994 Dec; 6(12):1839-47. PubMed ID: 7535094
[TBL] [Abstract][Full Text] [Related]
15. Differences in kappa to lambda (kappa:lambda) ratios of serum and urinary free light chains.
Abe M; Goto T; Kosaka M; Wolfenbarger D; Weiss DT; Solomon A
Clin Exp Immunol; 1998 Feb; 111(2):457-62. PubMed ID: 9486419
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.
Wolf Pérez AM; Lorenzen N; Vendruscolo M; Sormanni P
Methods Mol Biol; 2022; 2313():57-113. PubMed ID: 34478132
[TBL] [Abstract][Full Text] [Related]
17. Significant Differences in Physicochemical Properties of Human Immunoglobulin Kappa and Lambda CDR3 Regions.
Townsend CL; Laffy JM; Wu YB; Silva O'Hare J; Martin V; Kipling D; Fraternali F; Dunn-Walters DK
Front Immunol; 2016; 7():388. PubMed ID: 27729912
[TBL] [Abstract][Full Text] [Related]
18. AB-Amy: machine learning aided amyloidogenic risk prediction of therapeutic antibody light chains.
Zhou Y; Huang Z; Gou Y; Liu S; Yang W; Zhang H; Dzisoo AM; Huang J
Antib Ther; 2023 Jul; 6(3):147-156. PubMed ID: 37492587
[TBL] [Abstract][Full Text] [Related]
19. Comparing domain interactions within antibody Fabs with kappa and lambda light chains.
Toughiri R; Wu X; Ruiz D; Huang F; Crissman JW; Dickey M; Froning K; Conner EM; Cujec TP; Demarest SJ
MAbs; 2016 Oct; 8(7):1276-1285. PubMed ID: 27454112
[TBL] [Abstract][Full Text] [Related]
20. The repertoire of human antibody to the Haemophilus influenzae type b capsular polysaccharide.
Insel RA; Adderson EE; Carroll WL
Int Rev Immunol; 1992; 9(1):25-43. PubMed ID: 1484268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
